Axsome Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Axsome Therapeutics' es Herriot Tabuteau , nombrado en Jan 2012, tiene una permanencia de 12.42 años. compensación anual total es $9.90M, compuesta por 7.6% salario y 92.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.015% de las acciones de la empresa, por valor de $549.39K. La antigüedad media del equipo directivo y de la junta directiva es de 5 años y 9.5 años, respectivamente.
Información clave
Herriot Tabuteau
Chief Executive Officer (CEO)
US$9.9m
Compensación total
| Porcentaje del salario del CEO | 7.6% |
| Permanencia del CEO | 12.7yrs |
| Participación del CEO | 0.02% |
| Permanencia media de la dirección | 6.3yrs |
| Promedio de permanencia en la Junta Directiva | 9.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult
Sep 06
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Aug 06Axsome Therapeutics: Lots Of Moving Parts
Jul 23Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?
Jul 02Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$309m |
| Mar 31 2024 | n/a | n/a | -US$296m |
| Dec 31 2023 | US$10m | US$750k | -US$239m |
| Sep 30 2023 | n/a | n/a | -US$202m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$159m |
| Dec 31 2022 | US$8m | US$685k | -US$187m |
| Sep 30 2022 | n/a | n/a | -US$160m |
| Jun 30 2022 | n/a | n/a | -US$150m |
| Mar 31 2022 | n/a | n/a | -US$141m |
| Dec 31 2021 | US$8m | US$685k | -US$130m |
| Sep 30 2021 | n/a | n/a | -US$126m |
| Jun 30 2021 | n/a | n/a | -US$114m |
| Mar 31 2021 | n/a | n/a | -US$100m |
| Dec 31 2020 | US$7m | US$575k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$95m |
| Mar 31 2020 | n/a | n/a | -US$90m |
| Dec 31 2019 | US$5m | US$435k | -US$68m |
| Sep 30 2019 | n/a | n/a | -US$53m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$1m | US$435k | -US$31m |
| Sep 30 2018 | n/a | n/a | -US$29m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$26m |
| Dec 31 2017 | US$1m | US$435k | -US$29m |
Compensación vs. Mercado: La compensación total de Herriot($USD9.90M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.83M).
Compensación vs. Ingresos: La compensación de Herriot ha aumentado mientras la empresa no es rentable.
CEO
Herriot Tabuteau (56 yo)
12.7yrs
Permanencia
US$9,896,629
Compensación
Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Fina...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 12.7yrs | US$9.90m | 0.015% $ 648.0k | |
| Chief Financial Officer | 6.3yrs | US$3.57m | 0.088% $ 3.8m | |
| Chief Operating Officer | 8.9yrs | US$4.04m | 0.012% $ 518.5k | |
| General Counsel & Secretary | 2.8yrs | US$3.06m | 0% $ 0 | |
| Executive VP & Head of Commercial | less than a year | sin datos | sin datos |
6.3yrs
Permanencia media
46.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de AXSM es experimentado (5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 12.7yrs | US$9.90m | 0.015% $ 648.0k | |
| Independent Lead Director | 9.8yrs | US$400.34k | 0.35% $ 15.0m | |
| Independent Director | 9.8yrs | US$405.34k | 0.021% $ 923.4k | |
| Independent Director | less than a year | US$417.48k | 0% $ 0 | |
| Independent Director | 9.8yrs | US$427.84k | 0.030% $ 1.3m |
9.8yrs
Permanencia media
56yo
Promedio de edad
Junta con experiencia: La junta directiva de AXSM se considera experimentada (9.5 años de antigüedad promedio).